Plonmarlimab, a GM-CSF-neutralizing antibody, produced an 83.3% response rate in a Phase 2 trial for refractory macrophage activation syndrome, according to the clinical update. The results add to the evidence base for targeting inflammatory cytokine drivers in this often fatal hyperinflammatory condition. The high response rate could impact how clinicians sequence immunomodulatory therapies and supports further development or expansion into broader patient subsets, including faster-responding phenotypes.
Get the Daily Brief